相似文献
1
Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency.
ACS Med Chem Lett. 2012 Oct 26;3(12):991-996. doi: 10.1021/ml3002117.
2
Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors.
Neuropharmacology. 2000 Feb 14;39(4):586-98. doi: 10.1016/s0028-3908(99)00180-x.
3
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
J Pharmacol Exp Ther. 1995 Nov;275(2):885-98.
4
Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride.
Synapse. 1995 Jan;19(1):1-13. doi: 10.1002/syn.890190102.
5
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
J Pharmacol Exp Ther. 1995 Nov;275(2):899-913.
6
Biphasic inhibition of stimulated endogenous dopamine release by 7-OH-DPAT in slices of rat nucleus accumbens.
Br J Pharmacol. 1995 Jun;115(3):421-6. doi: 10.1111/j.1476-5381.1995.tb16350.x.
7
8
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
J Pharmacol Exp Ther. 1998 Oct;287(1):187-97.
9
Analysis of D2 and D3 receptor-selective ligands in rats trained to discriminate cocaine from saline.
Pharmacol Biochem Behav. 1999 Oct;64(2):373-8. doi: 10.1016/s0091-3057(99)00064-7.
10
Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors.
Pol J Pharmacol. 2001 Nov-Dec;53(6):571-6.
引用本文的文献
1
β2-Adrenergic Receptor Utilizes Distinct Interaction Interfaces to Selectively form Heterooligomers with a Subset of Bitter Taste Receptors.
Biochemistry. 2025 Aug 5;64(15):3219-3236. doi: 10.1021/acs.biochem.5c00208. Epub 2025 Jul 9.
2
Perry Disease: Current Outlook and Advances in Drug Discovery Approach to Symptomatic Treatment.
Int J Mol Sci. 2024 Oct 3;25(19):10652. doi: 10.3390/ijms251910652.
3
Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein.
Bioorg Med Chem. 2023 Jan 15;78:117131. doi: 10.1016/j.bmc.2022.117131. Epub 2022 Dec 16.
4
GPCR heteromers: An overview of their classification, function and physiological relevance.
Front Endocrinol (Lausanne). 2022 Aug 30;13:931573. doi: 10.3389/fendo.2022.931573. eCollection 2022.
5
2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.
J Med Chem. 2020 Mar 12;63(5):1779-1797. doi: 10.1021/acs.jmedchem.9b01105. Epub 2019 Sep 24.
6
An Update on Non-CB, Non-CB Cannabinoid Related G-Protein-Coupled Receptors.
Cannabis Cannabinoid Res. 2017 Oct 1;2(1):265-273. doi: 10.1089/can.2017.0036. eCollection 2017.
7
Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
Curr Neuropharmacol. 2018 Jan 30;16(2):222-230. doi: 10.2174/1570159X15666170518151127.
8
Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders.
Front Neurosci. 2016 Sep 13;10:406. doi: 10.3389/fnins.2016.00406. eCollection 2016.
9
Structure-guided development of heterodimer-selective GPCR ligands.
Nat Commun. 2016 Jul 26;7:12298. doi: 10.1038/ncomms12298.
10
PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor.
ACS Med Chem Lett. 2015 Mar 13;6(4):425-9. doi: 10.1021/ml500478m. eCollection 2015 Apr 9.
本文引用的文献
1
Homobivalent ligands of the atypical antipsychotic clozapine: design, synthesis, and pharmacological evaluation.
J Med Chem. 2012 Feb 23;55(4):1622-34. doi: 10.1021/jm201420s. Epub 2012 Feb 2.
2
The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H₂ receptor agonists.
J Med Chem. 2012 Feb 9;55(3):1147-60. doi: 10.1021/jm201128q. Epub 2012 Jan 25.
3
Bivalent molecular probes for dopamine D2-like receptors.
Bioorg Med Chem. 2012 Jan 1;20(1):455-66. doi: 10.1016/j.bmc.2011.10.063. Epub 2011 Oct 25.
4
Development of a bivalent dopamine D₂ receptor agonist.
J Med Chem. 2011 Nov 24;54(22):7911-9. doi: 10.1021/jm2009919. Epub 2011 Oct 31.
5
Bivalent dopamine D2 receptor ligands: synthesis and binding properties.
J Med Chem. 2011 Jul 14;54(13):4896-903. doi: 10.1021/jm2004859. Epub 2011 Jun 3.
6
Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.
J Med Chem. 2010 Oct 14;53(19):7048-60. doi: 10.1021/jm1006676.
7
Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies.
Biochem Pharmacol. 2011 Jan 1;81(1):157-63. doi: 10.1016/j.bcp.2010.08.026. Epub 2010 Sep 15.
8
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.
J Med Chem. 2010 Mar 11;53(5):2114-25. doi: 10.1021/jm901618d.
9
Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules.
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2693-8. doi: 10.1073/pnas.0907915107. Epub 2010 Jan 20.
10
Structural diversity of G protein-coupled receptors and significance for drug discovery.
Nat Rev Drug Discov. 2008 Apr;7(4):339-57. doi: 10.1038/nrd2518.
Zotero 插件